LLY

779.27

+0.36%↑

JNJ

152.59

+0.17%↑

ABBV

185.69

+1.88%↑

NVO

69.01

+0.7%↑

UNH

311.78

+0.98%↑

LLY

779.27

+0.36%↑

JNJ

152.59

+0.17%↑

ABBV

185.69

+1.88%↑

NVO

69.01

+0.7%↑

UNH

311.78

+0.98%↑

LLY

779.27

+0.36%↑

JNJ

152.59

+0.17%↑

ABBV

185.69

+1.88%↑

NVO

69.01

+0.7%↑

UNH

311.78

+0.98%↑

LLY

779.27

+0.36%↑

JNJ

152.59

+0.17%↑

ABBV

185.69

+1.88%↑

NVO

69.01

+0.7%↑

UNH

311.78

+0.98%↑

LLY

779.27

+0.36%↑

JNJ

152.59

+0.17%↑

ABBV

185.69

+1.88%↑

NVO

69.01

+0.7%↑

UNH

311.78

+0.98%↑

Search

Madrigal Pharmaceuticals Inc

Fechado

SetorSaúde

302.46 0.6

Visão Geral

Variação de preço das ações

24h

Atual

Mín

298.02

Máximo

305.47

Indicadores-chave

By Trading Economics

Rendimento

-14M

-73M

Vendas

34M

137M

EPS

-3.32

Margem de lucro

-53.361

Funcionários

528

EBITDA

-14M

-70M

Recomendações

By TipRanks

Recomendações

Compra Forte

Previsão para 12 meses

+42.28% upside

Dividendos

By Dow Jones

Próximos Ganhos

6 de ago. de 2025

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

-971M

6.3B

Abertura anterior

301.86

Fecho anterior

302.46

Sentimento de Notícias

By Acuity

50%

50%

138 / 380 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Very Strong Bearish Evidence

Madrigal Pharmaceuticals Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

29 de jun. de 2025, 23:59 UTC

Conversa de Mercado

Oil Falls Amid Abating Middle East Tensions -- Market Talk

29 de jun. de 2025, 23:47 UTC

Conversa de Mercado

Gold Edges Lower Amid Trade Deal Hopes, Risk Appetite -- Market Talk

29 de jun. de 2025, 23:39 UTC

Conversa de Mercado

Nikkei May Rise, Tracking Wall Street's Gains -- Market Talk

29 de jun. de 2025, 22:48 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

29 de jun. de 2025, 22:48 UTC

Conversa de Mercado

Export Data Buoy Fisher & Paykel Healthcare Bull -- Market Talk

28 de jun. de 2025, 08:20 UTC

Conversa de Mercado

Financial Services Roundup: Market Talk

28 de jun. de 2025, 08:20 UTC

Conversa de Mercado

Tech, Media & Telecom Roundup: Market Talk

27 de jun. de 2025, 20:51 UTC

Ganhos

These Stocks Moved the Most Today: Nike, Nvidia, Coinbase, Palantir, Boeing, Newmont, Core Scientific, and More -- Barrons.com

27 de jun. de 2025, 20:50 UTC

Conversa de Mercado

Tech, Media & Telecom Roundup: Market Talk

27 de jun. de 2025, 20:50 UTC

Conversa de Mercado

Financial Services Roundup: Market Talk

27 de jun. de 2025, 20:48 UTC

Conversa de Mercado

Computer Lobby Cheers Move to Punish Canada Over Digital Tax -- Market Talk

27 de jun. de 2025, 20:46 UTC

Conversa de Mercado

Market Talk Roundup: Latest on U.S. Politics

27 de jun. de 2025, 20:46 UTC

Conversa de Mercado

Canada Dismissal of Risk From Digital Tax Is 'Shocking' -- Market Talk

27 de jun. de 2025, 19:31 UTC

Conversa de Mercado

Canada CEOs Call for Carney to Drop Digital Tax -- Market Talk

27 de jun. de 2025, 19:19 UTC

Conversa de Mercado

Oil Posts Weekly Loss As Geopolitical Premium Evaporates -- Market Talk

27 de jun. de 2025, 19:16 UTC

Conversa de Mercado

U.S. Natural Gas Futures Snap Losing Streak -- Market Talk

27 de jun. de 2025, 18:57 UTC

Aquisições, Fusões, Aquisições de Empresas

Russian Oligarch Roman Abramovich Is Evraz PLC's Largest Shareholder With 29% Stake -- WSJ

27 de jun. de 2025, 18:57 UTC

Aquisições, Fusões, Aquisições de Empresas

Evraz North America Parent Evraz PLC Remains Under Sanction by U.K. -- WSJ

27 de jun. de 2025, 18:57 UTC

Aquisições, Fusões, Aquisições de Empresas

Evraz North America Employs About 3,400 People, Has 3.5 Million Tons of Finished Steel Capacity -- WSJ

27 de jun. de 2025, 18:57 UTC

Aquisições, Fusões, Aquisições de Empresas

Atlas Holdings to Buy Evraz North America for Up to $500 Million, Companies Say -- WSJ

27 de jun. de 2025, 18:57 UTC

Aquisições, Fusões, Aquisições de Empresas

Atlas Holdings to Buy Evraz North America for Up to $500 Million, Companies Say -- WSJ

27 de jun. de 2025, 18:42 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

27 de jun. de 2025, 18:42 UTC

Conversa de Mercado

Canada's Carney 'Likely Amenable' to Dropping Digital-Services Tax -- Market Talk

27 de jun. de 2025, 18:39 UTC

Conversa de Mercado
Ganhos

Nike's Second-Half Prospects Can Get Better as Worst is Behind it -- Market Talk

27 de jun. de 2025, 18:29 UTC

Conversa de Mercado

Canada Recession Risks Likely to Rise With Trump's Termination of Tariff Talks -- Market Talk

27 de jun. de 2025, 18:18 UTC

Conversa de Mercado

Canadian Dollar Sharply Weakens on Trump's Surprise End to US-Canada Tariff Talks -- Market Talk

27 de jun. de 2025, 18:16 UTC

Conversa de Mercado

Trump's Threat Against Canada Weighs Down Treasurys -- Market Talk

27 de jun. de 2025, 17:16 UTC

Conversa de Mercado

U.S. Oil Rig Count Falls by 6 to 432 -- Market Talk

27 de jun. de 2025, 17:08 UTC

Ganhos

McDonald's Stock Has Slipped. One Analyst Sees 21% Upside. -- Barrons.com

27 de jun. de 2025, 16:52 UTC

Aquisições, Fusões, Aquisições de Empresas

Nike Stock Soars After Earnings. Is It Time to Just Buy It? -- Barrons.com

Comparação entre Pares

Variação de preço

Madrigal Pharmaceuticals Inc Previsão

Preço-alvo

By TipRanks

42.28% parte superior

Previsão para 12 meses

Média 427.91 USD  42.28%

Máximo 540 USD

Mínimo 248 USD

Com base em 13 analistas de Wall Street que oferecem metas de preço de 12 meses para Madrigal Pharmaceuticals Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

13 ratings

11

Comprar

1

Manter

1

Vender

Pontuação Técnica

By Trading Central

263.2 / 277.1Suporte e Resistência

Curto Prazo

Very Strong Bearish Evidence

Médio Prazo

Strong Bearish Evidence

Longo Prazo

Neutral Evidence

Sentimento

By Acuity

138 / 380 Ranking em Saúde

Sentimento de Notícias

Neutral

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Abaixo da média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Madrigal Pharmaceuticals Inc

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.